Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RNTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Nasaruplase Gamma (LTI-01) | Pleural Effusion | Phase 2 · NCT04159831 | Completed |
| LTI-03 | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 · NCT06968845 | Recruiting |
| Caveolin-1-Scaffolding-Protein-Derived Peptide… | Idiopathic Pulmonary Fibrosis | Phase 1 · NCT04233814 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RNTX holds $43.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $6M/quarter from operations, an estimated runway of 21.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 48 · Elevated
Management believes that, based on the Company’s current operating plan, the Company’s cash, cash equivalents and investments of $ 36,487 as of September 30, 2026 will be sufficient to enable the Company to fund its planned operating expense and capital expenditure requirements into the first quarter of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RNTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BIOS CAPITAL MANAGEMENT, LP | 5%+ holder (13G) | 7,797,502 | 9.04% | 2026-05-06 |
| Voss Capital, LP 10% owner |
Insider | 5,656,957 | 6.56% | 2026-06-30 |
| Funicular Funds, LP | 5%+ holder (13G) | 5,195,000 | 6.02% | 2026-05-01 |
| ADAR1 Capital Management, LLC | Institution (13G, 5%+) | 4,500,000 | 5.22% | 2026-06-30 |
| Lynwood Capital Management Inc. | 5%+ holder (13G) | 4,280,500 | 4.96% | 2026-06-30 |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT 10% owner |
Insider | 1,746,549 | 2.02% | 2024-06-14 |
| Rickenbach Josef H Von Director · +60,675 options |
Insider | 62,514 | 0.07% | 2026-05-21 |
| James Brian Windsor President and Chief Executive Officer, D · +667,500 options |
Insider | 27,046 | 0.03% | 2026-04-30 |
Share count 86,267,032 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RNTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →